Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-CD56 CAR T cells
- Development stage
- Unknown
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-CD56 CAR T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy developed by The Affiliated Hospital of Xuzhou Medical University. This cell therapy is engineered to target CD56 (Neural Cell Adhesion Molecule 1, NCAM1), a glycoprotein typically expressed on the surface of natural killer (NK) cells and certain T-cell subsets, which is also highly expressed in various hematologic malignancies including extranodal NK/T-cell lymphoma (ENKTL) and aggressive NK-cell leukemia (ANKL). The treatment involves the infusion of T cells modified to express a CAR that recognizes CD56, leading to the targeted destruction of CD56-positive tumor cells. It is currently being evaluated in clinical trials for patients with relapsed or refractory NK/T-cell malignancies, often following a lymphodepleting conditioning regimen of fludarabine and cyclophosphamide.
- Other names
- Anti-CD56-CAR TAnti-CD-56-CAR TAnti-CD 56-CAR TCD56-targeted CAR-T cellsCD-56-targeted CAR-T cellsCD 56-targeted CAR-T cells
Beyond the preview
Go deeper on Anti-CD56 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-CD56 CAR T cells.